Financial Times The three cases are all very different but together they create the impression of an industry in flux as it searches for a new growth model after a decade-long wilderness of patent expiries and misfiring development pipelines. “The plates are ... Like ...
Huffington Post Canada China , which currently spends 1.7 per cent, is set to overtake the EU by 2019 and the US by 2023. Germany is in a fairly good ... The fourth part of my action plan is a traditional one: Return to the social market economy and cut red tape! As a result ...
Wall Street Journal Restated for this effect, sales were up 8.5%, driven by strong volume growth in China (notably Decapeptyl(R) and Smecta(R) ), the Middle East and Brazil where Dysport(R) sales recorded good performance in aesthetics and therapeutics. ... difficulties ... and more »
Seeking Alpha Prescription -only medications , such as full-strength NSAIDs (both with and without proton pump inhibitors), COX-2 selective NSAIDs, oral opiate analgesics, and topical NSAIDs are also available. We estimate that in 2012, topical ... Nuvo has licensed ... and more »
Business Mirror To relieve pain and to help you cope with the symptoms, your pain doctor may prescribe antidepressants or muscle relaxants to reduce pain perception in your brain. Usually, the first line of treatment involves physical therapy, exercise, eating a well ...
Insurance News Net (press release) Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8 percent and 4.5 percent, respectively, of total revenue. In terms of distribution channels, the proportion of ... But due to policy ...
Women of China A young mother named Cheng was bewildered about how to divide a Hismanal tablet into quarters, as her new-born baby developed skin rashes and was prescribed with one quarter of a tablet per day by the doctor. Cheng used a knife to cut the tablet while ...
The Herald | HeraldOnline.com (press release) Then what comes the next are Chinese patent medicine and traditional Chinese medicinal materials, which occupied 16.8% and 4.5%, respectively, of total revenue. In terms of distribution channels, the proportion of ... But due to policy restriction ... and more »
Financial Times The three cases are all very different but together they create the impression of an industry in flux as it searches for a new growth model after a decade-long wilderness of patent expiries and misfiring development pipelines. “The plates are ... Like ...
Wall Street Journal Restated for this effect, sales were up 8.5%, driven by strong volume growth in China (notably Decapeptyl(R) and Smecta(R) ), the Middle East and Brazil where Dysport(R) sales recorded good performance in aesthetics and therapeutics. ... difficulties ... and more »
